April 30, 2025

VMD approves latest addition to MSD Animal Health’s BRAVECTO® portfolio, giving vets and dog owners more choice in parasite prevention

BRAVECTO^® TriUNO targets internal and external parasites
The new monthly chewable formulation is suitable for puppies
This latest addition delivers more choice for dog owners and veterinary practices to utilise BRAVECTO® throughout all life stages of the pet

Milton Keynes, UK, – 30th April 2025 – MSD Animal Health UK Ltd, a subsidiary of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that the Veterinary Medicines Directorate has granted the marketing authorisation for BRAVECTO^® TriUNO, a new formulation of BRAVECTO (fluralaner) for dogs that targets both external and internal parasites. The monthly, chewable tablet will be available through licensed veterinarians and has already been approved by regulatory agencies in Europe, Peru, Guatemala, Nicaragua, and Costa Rica.

“With this latest formulation of BRAVECTO, MSD Animal Health is giving veterinarians and dog owners a greater range of convenient options for protecting their dog year-round from parasites, and all from the same trusted BRAVECTO portfolio,” said Victoria Miles, UK Companion Animal Director, MSD Animal Health.

BRAVECTO TriUNO is approved for the treatment of tick and flea infestations in dogs providing immediate and persistent flea (Ctenocephalides felis and C. canis) and tick (Dermacentor reticulatus, Ixodes hexagonus, Ixodes ricinus, and Rhipicephalus sanguineus)killing activityfor one month.

It is also approved for the treatment of infections with gastrointestinal nematodes of the following species: roundworms (adult stages of Toxocara canis, and adult stages of Toxascaris leonina)and hookworms (L4, immature adult (L5), and adult stages of Ancylostoma caninum and adult stages of Uncinaria stenocephala), for the prevention of heartworm disease (caused by Dirofilaria immitis), and for the prevention of angiostrongylosis (by reduction of the level of infection with immature adult (L5) and adult stages of Angiostrongylus vasorum).

Since its introduction in 2014, BRAVECTO has provided long-lasting flea and tick protection, with more than 350 million doses distributed in 100 countries. BRAVECTO is available in a variety of formulations with products for both cats and dogs. Within the BRAVECTO range for dogs, there is already a 12-week chew and a one-year injection, both for the prevention of external parasites.

Miles added: “We see BRAVECTO TriUNO as a great option for puppies that require a monthly wormer on top of protection against fleas and ticks. This also gives flexibility later on for the dog to remain with the Bravecto brand but be swapped onto a longer-duration flea and tick product with a wormer administered according to a veterinarian’s risk-based assessment.”

BRAVECTO TriUNO is available as a flavoured chewable tablet indicated for dogs and puppies from 8 weeks of age and at least 1.27 Kg body weight and can be administered monthly to dogs at risk of infestation by multiple types of internal and external parasites. It contains three anti-parasitic ingredients including fluralaner, which provides activity against ticks and fleas, moxidectin, which provides systemic activity against non-intestinal worms, and pyrantel, which provides activity against intestinal worms.

BRAVECTO TriUNO quickly treats existing fleas and ticks on dogs following treatment and continues to kill newly acquired fleas and ticks for an entire month following treatment. Additionally, roundworms are also effectively treated with BRAVECTO TriUNO, alongside the prevention for heartworm and lungworm. In many European countries mosquitoes transmit heartworm from dog to dog, and lungworm is transmitted to dogs by the ingestion of infected slugs and snails.

###

About MSD Animal Health

At MSD, known as Merck & Co., Inc., Rahway, N.J., USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we’ve been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world’s most challenging diseases. MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA, is the global animal health business of MSD. Through its commitment to The Science of Healthier Animals^®, MSD Animal Health offers veterinarians, farmers, producers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of connected technology that includes identification, traceability and monitoring products. MSD Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. MSD Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.msd-animal-health.com and connect with us on LinkedIn and X (formerly Twitter).

Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA

This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

###

BRAVECTO TriUno for dogs. Contains fluralaner, moxidectin and pyrantel. POM-V.

Further advice should be sought from the medicine prescriber. For more information, refer to the SPC, datasheet or package leaflet. Prescription decisions are for the person issuing the prescription alone.

Use medicines responsibly.